NDAC's Nov. 20-22 meeting to focus on vaginal contraceptive efficacy; STD prevention.
This article was originally published in The Tan Sheet
NDAC TO ADDRESS SPERMICIDAL EFFICACY DURING NOV. 20-22 JOINT MEETING with the Anti-Infective Drugs and Antiviral Drugs Advisory Committees and the Advisory Committee for Reproductive Health, formerly known as the Fertility and Maternal Health Advisory Committee. The Nonprescription Drugs Advisory Committee and the other groups are scheduled to consider the role of vaginal contraceptives in preventing HIV and chlamydia, and to discuss FDA's 1995 proposed rule for OTC vaginal contraceptives.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC